Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05897320 · ClinicalTrials.gov registry record · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
A Phase 3 study of Episodic Migraine, sponsored by H. Lundbeck A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 315
- Enrollment target
- 20
- Study locations
NCT05897320 is a Phase 3 study of Episodic Migraine that is actively recruiting participants, run by H. Lundbeck A/S. The registered enrollment target is 315 participants, below the 472-participant average among 13 other Episodic Migraine trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT05897320, a Phase 3 study of Episodic Migraine, is actively recruiting participants, sponsored by H. Lundbeck A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 315 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eptinezumab
Study Locations (20)
Florida
- Child Neurology of NW Florida - Gulf Breeze
- AGA Clinical Trials - Hialeah
- University of South Florida - 13330 USF Laurel Dr - Tampa
Ohio
- Childrens Hospital Medical Center of Akron - Akron
- Cincinnati Children's Hospital Medical Center - PIN - Cincinnati
Ciudad Autónoma de BuenosAires
- Hospital Britanico de Buenos Aires - Barracas
- Expertia S.A- Mautalén Salud e Investigación - Buenos Aires
Connecticut
- Ki Health Partners LLC DBA New England Institute for Clinical Research - Stamford
Georgia
- Clinical Integrative Research Center of Atlanta - Atlanta
Kentucky
- University of Kentucky HealthCare (UKHC) Kentucky Clinic - Lexington
Maryland
- University of Maryland School of Medicine - Baltimore
Michigan
- Michigan Head Pain and Neurological Institute - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2023-06-08 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05897320
The ClinicalTrials.gov registry entry for NCT05897320 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 472-participant average among 13 other Episodic Migraine trials with a reported enrollment target (33% lower). The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Episodic Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05897320 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, Ohio, Ciudad Autónoma de BuenosAires.
Frequently Asked Questions
What is clinical trial NCT05897320 about?
NCT05897320 is a clinical study titled "A Study of Eptinezumab in Pediatric Participants With Episodic Migraine". The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
What is the current status of trial NCT05897320?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 315 participants. The study started on 2023-06-08. Estimated completion is 2027-08-31.
What conditions does trial NCT05897320 study?
This clinical trial studies the following conditions: Episodic Migraine.
What interventions are being tested in trial NCT05897320?
The interventions under investigation include: Placebo (DRUG), Eptinezumab (DRUG).
Who is sponsoring clinical trial NCT05897320?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05897320 being conducted?
This trial has 20 study locations across Connecticut, Florida, Georgia, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Episodic Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
RECRUITING · Phase 3
-
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
ACTIVE NOT RECRUITING · Phase 3
-
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)
COMPLETED · Phase 3
-
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.